[1]黄馨禾,董丹丹,刘 倩.PARP抑制剂在卵巢癌治疗中的研究现状[J].医学信息,2019,32(21):26-29.[doi:10.3969/j.issn.1006-1959.2019.21.010]
　HUANG Xin-he,DONG Dan-dan,LIU Qian.Research Status of PARP Inhibitors in the Treatment of Ovarian Cancer[J].Journal of Medical Information,2019,32(21):26-29.[doi:10.3969/j.issn.1006-1959.2019.21.010]
点击复制

PARP抑制剂在卵巢癌治疗中的研究现状()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
32卷
期数:
2019年21期
页码:
26-29
栏目:
综述
出版日期:
2019-11-01

文章信息/Info

Title:
Research Status of PARP Inhibitors in the Treatment of Ovarian Cancer
文章编号:
1006-1959（2019）21-0026-04
作者:
黄馨禾; 董丹丹; 刘 倩
（哈尔滨医科大学附属第二医院妇产科，黑龙江 哈尔滨 165000）
Author(s):
HUANG Xin-he; DONG Dan-dan; LIU Qian
(Department of Obstetrics and Gynecology,the Second Affiliated Hospital of Harbin Medical University,Harbin 165000,Heilongjiang,China)
关键词:
卵巢癌; ADP核糖聚合酶; 乳腺癌相关抗原; 同源重组
Keywords:
Ovarian cancer; ADP ribose polymerase; Breast cancer-associated antigen; Homologous recombination
分类号:
R737.31
DOI:
10.3969/j.issn.1006-1959.2019.21.010
文献标志码:
A
摘要:
ADP核糖聚合酶（PARP）抑制剂是目前已知对于上皮性卵巢癌（EOC）治疗效果较好的药物。高级别浆液性癌是上皮性卵巢癌中最常见的组织学亚型，由于其同源重组缺乏率（HR）较高，PARP抑制剂对其效果尤为明显。PARP抑制剂通过破坏DNA修复，促进肿瘤细胞的死亡。已有研究表明，对于伴有BRCA1/2突变或铂敏感性的复发性上皮性卵巢癌妇女，PARP抑制剂的效果十分显著。目前已有3种PARP抑制剂（Olaparib、Niraparib和Rucaparib）现在被批准用于对铂敏感和铂敏感复发患者的维持治疗。此外，PARP抑制剂也被批准用于有3种或3种以上的既往治疗的伴有BRCA1/2突变的复发性EOC患者的积极治疗。本文主要对EOC中PARP抑制剂的研究现状进行综述。
Abstract:
ADP ribose polymerase (PARP) inhibitors are currently the best known agents for the treatment of epithelial ovarian cancer (EOC). High-grade serous carcinoma is the most common histological subtype of epithelial ovarian cancer. Because of its high homologous recombination rate (HR), PARP inhibitors are particularly effective. PARP inhibitors promote tumor cell death by disrupting DNA repair. Studies have shown that the effect of PARP inhibitors is significant for women with recurrent epithelial ovarian cancer with BRCA1/2 mutation or platinum sensitivity. Three PARP inhibitors (Olaparib, Niraparib, and Rucaparib) are currently approved for maintenance therapy in patients with platinum-sensitive and platinum-sensitive relapses. In addition, PARP inhibitors have also been approved for active treatment of patients with recurrent EOC with BRCA1/2 mutations with 3 or more prior treatments. This paper reviews the research status of PARP inhibitors in EOC.

参考文献/References:

[1]Siegel RL,Miller KD,Jemal A.Cancer statistics,2017[J].CA Cancer J Clin,2017,67(1):7-30. [2]Chen Y,Du H.The promising PARP inhibitors in ovarian cancer therapy:from olaparib to others[J].Biomed Pharmacother,2018(99):55-60. [3]Kurman RJ,Carcangiu ML,Herrington CS.World Health Organisation classification of tumours of the female reproductive organs 4th ed[M].IARC,2014. [4]张国楠,黄建鸣.对卵巢癌治疗中PARP抑制剂适应证从BRCA突变到HRD、铂敏感变迁的思考[J].中国实用妇科与产科杂志,2019,35(5):551-553. [5]Chao A,Chang TC,Lapke N,et al.Prevalence and clinical significance of,BRCA1/2,germline and somatic mutations in Taiwanese patients with ovarian cancer[J].Oncotarget,2016,7(51):85529. [6]Heong VYM,Ong PY,Wan LY,et al.BRCA1/2 mutation frequency and patterns of treatment response in Asian women with ovarian, primary peritoneal or fallopian tube carcinoma(OPFC): experience from an Asian cancer centre[C].Asia Congress of the European-Society-for-Medical-Oncology(ESMO).2015. [7]Ledermann JA.Lessons learned from a decade of clinical trials of high-dose chemotherapy in ovarian cancer[J].Int J Gynecol Cancer,2008,18(Suppl 1):53-58. [8]Katsumata N,Yasuda M,Isonishi S,et al.Long-term results of dose-dense paclitaxel and carboplatin versus conventional paclitaxel and carboplatin for treatment of advanced epithelial ovarian,fallopian tube,or primary peritoneal cancer(JGOG 3016):a randomised, controlled,open-label trial[J].Lancet Oncol,2013,14(10):1020-1026. [9]徐林.紫杉醇联合顺铂腹腔注射晚期卵巢癌患者的疗效及对生存期的影响[J].实用癌症杂志,2018,33(4):638-640. [10]徐倩文.贝伐单抗联合化疗治疗卵巢癌的有效性及安全性[J].首都食品与医药,2018,25,470(11):48. [11]毛伴云.全基因组拷贝数变异与卵巢肿瘤异质性的关联研究[D].北京协和医学院;中国医学科学院;清华大学医学部;北京协和医学院中国医学科学院,2017. [12]Ashworth A,Lord CJ.Synthetic lethal therapies for cancer:what's next after PARP inhibitors[J].Nat Rev Clin Oncol,2018,15(9):564-576. [13]Ashworth A.A synthetic lethal therapeutic approach:poly(ADP)ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair[J].J Clin Oncol,2008,26(22):3785-3790. [14]Ohmoto A,Yachida S.Current status of poly(ADP-ribose)polymerase inhibitors and future directions[J].Onco Targets Ther,2017(10):5195-5208. [15]Konstantinopoulos PA,Matulonis UA.PARP inhibitors in ovarian cancer:a trailblazing and transformative journey[J].Clin Cancer Res,2018,24(17):4062-4065. [16]Ledermann JA,Drew Y,Kristeleit RS.Homologous recombination deficiency and ovarian cancer[J].Eur J Cancer,2016(60):49-58. [17]Haluska P,Timms KM,Alhilli M,et al.214 Homologous recombination deficiency(HRD)score and niraparib efficacy in high grade ovarian cancer[J].European Journal of Cancer,2014,50(6):72-73. [18]Incorvaia L,Passiglia F,Rizzo S,et al."Back to a false normality":new intriguing mechanisms of resistance to PARP inhibitors[J].Oncotarget,2017,8(14):23891-23904. [19]Gelmon KA,Tischkowitz M,Mackay H,et al.Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer:a phase 2,multicentre,open-label,non-randomised study[J].Lancet Oncol,2011,12(9):852-861. [20]Den Brok WD,Schrader KA,Sun S,et al.Homologous recombination deficiency in breast cancer:a clinical review[J].JCO Precis Oncol,2017(1):1-13. [21]Coleman RL,Oza AM,Lorusso D,et al.Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy(ARIEL3):a randomised,double-blind, placebocontrolled,phase 3 trial[J].Lancet,2017,390(10106):1949-1961. [22]Ledermann J,Harter P,Gourley C,et al.Olaparib Maintenance Therapy in Patients With Platinum-Sensitive Relapsed Serous Ovarian Cancer[J].Obstetrical&Gynecological Survey,2014,69(10):594-596. [23]Mirza MR,Monk BJ,Herrstedt J,et al.Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer[J].N Engl J Med,2016,375(22):2154-2164. [24]Kaufman B,Shapira-Frommer R,Schmutzler RK,et al.Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation[J].J Clin Oncol,2015,33(3):244-250. [25]Swisher EM,Lin KK,Oza AM,et al.Rucaparib in relapsed,platinum-sensitive high-grade ovarian carcinoma(ARIEL2 Part 1):an international,multicentre,open-label,phase 2 trial[J]. Lancet Oncol,2017,18(1):75-87. [26]Moore KN,Mirza MR,Matulonis UA.The poly(ADP ribose)polymerase inhibitor niraparib: management of toxicities[J].Gynecol Oncol,2018,149(1):214-220. [27]Lermann J,Harter P,Gourley C,et al.Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer:a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial[J].Lancet Oncol,2014,15(8):852-861. [28]Pujade-Lauraine E,Ledermann JA,Selle F,et al.Olaparib tablets as maintenance therapy in patients with platinum-sensitive,relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21):a double-blind,randomised,placebo-controlled,phase 3 trial[J].Lancet Oncol,2017,18(9):1274-1284. [29]Moore K,Colombo N,Scambia G,et al.Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer[J].N Engl J Med,2018,379(26):2495-2505. [30]Kaye SB,Lubinski J,Matulonis U,et al.PhaseⅡ,open-label,randomized,multicenter study comparing the efficacy and safety of olaparib,a poly(ADP-ribose)polymerase inhibitor,and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer[J].J Clin Oncol,2012,30(4):372-379. [31]Kristeleit R,Shapiro GI,Burris HA,et al.A phaseⅠ-Ⅱstudy of the oral PARP inhibitor rucaparib in patients with germline BRCA1/2-mutated ovarian carcinoma or other solid tumors[J].Clin Cancer Res,2017,23(15):4095-4106. [32]Oza AM,Cibula D,Benzaquen AO,et al.Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer:a randomised phase 2 trial[J].Lancet Oncol, 2015,16(1):87-97. [33]Washington C,Gunderson CC,Moore KN.Update in the use and evaluation of poly(ADP-ribose) polymerase inhibitors in epithelial ovarian cancer[J].Current Opinion in Obstetrics& Gynecology,2019,31(1):4-11. [34]Kristeleit R,Shapiro GI,Burris HA,et al.A phaseⅠ-Ⅱstudy of the oral PARP inhibitor rucaparib in patients with germline BRCA1/2-mutated ovarian carcinoma or other solid tumors. Clin Cancer Res[J].2017,23(15):4095-4106.

相似文献/References:

[1]杨廷双.卵巢癌患者经CT检查和MRI检查的临床效果对比[J].医学信息,2018,31(07):153.[doi:10.3969/j.issn.1006-1959.2018.07.053]
　YANG Ting-shuang.Comparison of Clinical Effects between CT and MRI in Patients with Ovarian Cancer[J].Journal of Medical Information,2018,31(21):153.[doi:10.3969/j.issn.1006-1959.2018.07.053]
[2]揭嘉慧,张 颖.卵巢癌与非编码RNA研究进展[J].医学信息,2019,32(05):39.[doi:10.3969/j.issn.1006-1959.2019.05.014]
　JIE Jia-hui,ZHANG Ying.Progress in Research on Ovarian Cancer and Non-coding RNA[J].Journal of Medical Information,2019,32(21):39.[doi:10.3969/j.issn.1006-1959.2019.05.014]
[3]林斯婕,吴 璇,覃 桓,等.卵巢癌合并2型糖尿病发生的危险因素分析[J].医学信息,2019,32(05):124.[doi:10.3969/j.issn.1006-1959.2019.05.039]
　LIN Si-jie,WU Xuan,QIN Huan,et al.Analysis of Risk Factors for Ovarian Cancer Complicated with Type 2 Diabetes[J].Journal of Medical Information,2019,32(21):124.[doi:10.3969/j.issn.1006-1959.2019.05.039]
[4]李思文,张 燕.不同紫杉醇剂型联合卡铂治疗卵巢癌的疗效研究[J].医学信息,2019,32(07):150.[doi:10.3969/j.issn.1006-1959.2019.07.046]
　LI Si-wen,ZHANG Yan.Therapeutic Effect of Different Paclitaxel Dosage Forms Combined With Carboplatin On Ovarian Cancer[J].Journal of Medical Information,2019,32(21):150.[doi:10.3969/j.issn.1006-1959.2019.07.046]
[5]许书凡,庞 华.18F-FDGPET/CT在卵巢癌中的应用研究[J].医学信息,2019,32(08):75.[doi:10.3969/j.issn.1006-1959.2019.08.022]
　XU Shu-fan,PANG Hua.Research on the Application of 18F-FDGPET/CT in Ovarian Cancer[J].Journal of Medical Information,2019,32(21):75.[doi:10.3969/j.issn.1006-1959.2019.08.022]
[6]张秀芳,陈 萍.安罗替尼联合顺铂治疗晚期卵巢癌恶性腹腔积液的疗效观察[J].医学信息,2019,32(18):132.[doi:10.3969/j.issn.1006-1959.2019.18.044]
　ZHANG Xiu-fang,CHEN Ping.Efficacy of Erlotinib Combined with Cisplatin in the Treatment of Advanced Ovarian Cancer with Malignant Ascites[J].Journal of Medical Information,2019,32(21):132.[doi:10.3969/j.issn.1006-1959.2019.18.044]
[7]王 秦,张家佳,刘成桂,等.高表达IL-12卵巢癌细胞的建立[J].医学信息,2019,32(21):78.[doi:10.3969/j.issn.1006-1959.2019.21.024]
　WANG Qin,ZHANG Jia-jia,LIU Cheng-gui,et al.Establishment of High Expression of IL-12 Ovarian Cancer Cells[J].Journal of Medical Information,2019,32(21):78.[doi:10.3969/j.issn.1006-1959.2019.21.024]
[8]钟达媚,张 颖.PCG与卵巢癌关系的研究[J].医学信息,2020,33(01):28.[doi:10.3969/j.issn.1006-1959.2020.01.011]
　ZHONG Da-mei,ZHANG Ying.Study on the Relationship Between PCG and Ovarian Cancer[J].Journal of Medical Information,2020,33(21):28.[doi:10.3969/j.issn.1006-1959.2020.01.011]
[9]张晓黎,张 颖,陈国通,等.环状RNA在妇科恶性肿瘤中的研究进展[J].医学信息,2020,33(03):38.[doi:10.3969/j.issn.1006-1959.2020.03.012]
　ZHANG Xiao-li,ZHANG Ying,CHEN Guo-tong,et al.Study of Circular RNA in Gynecological Malignancies[J].Journal of Medical Information,2020,33(21):38.[doi:10.3969/j.issn.1006-1959.2020.03.012]
[10]魏绮琪,张 颖.miR-200c与卵巢癌关系的研究[J].医学信息,2020,33(03):53.[doi:10.3969/j.issn.1006-1959.2020.03.016]
　WEI Qi-qi,ZHANG Ying.Study on the Relationship Between miR-200c and Ovarian Cancer[J].Journal of Medical Information,2020,33(21):53.[doi:10.3969/j.issn.1006-1959.2020.03.016]

更新日期/Last Update: 2019-11-01